Pharmazeutischer Grade Nepafenac CAS 78281-72-8

Modell Nr.
py0367
moq
1kg
Mf.
C15h14n2o2
cas
78281-72-8
Transportpaket
25kg/Drum
Spezifikation
99%
Warenzeichen
Puya
Herkunft
China
Produktionskapazität
20ton/Year
Referenzpreis
$ 45.00 - 135.00
kontaktieren Sie uns

Produktbeschreibung

Nepafenac CAS 78281-72-8
Product Name Nepafenac
CAS NO. 78281-72-8
Purity 99%
Melting point 177-181 C
Appearance and shape Light yellow powder
API Nepafenac powder cas 78281-72-8 is a non-steroidal anti-inflammatory drug indicated for the prevention and treatment of inflammation and pain associated with cataract surgery. After administration, nepafenac penetrates the cornea and is rapidly metabolised to amfenac by hydrolases. Nepafenac and amfenac work by potently inhibiting COX-1 and COX-2 enzymes.
Pharmaceutical Grade Nepafenac CAS 78281-72-8 Pharmaceutical Grade Nepafenac CAS 78281-72-8
Appearance: Faint yellow to dark yellow powder
Assay :≥99.00%
Density: 1.249 g/cm3
Boiling Point: 562.5ºC at 760 mmHg
Melting Point: 177-181ºC
Flash Point: 294ºC
Refractive Index: 1.641
Storage Condition: Refrigerator
Solubility: DMSO: ≥5mg/mL

Safety Information of Nepafenac:
HS Code: 2924299090
Symbol: GHS09
Caution Statement: P273
Signal Word: Warning
Hazard Declaration: H400
Hazard Code: N
Risk Statements: R50/53
Safety Statements: S60-61
RIDADR: UN 3077 9 / PGIII
WGK Germany: 3

Specification

Items

Standards

Results

Appearance

Yellow or light yellow crystalline powder

Conforms

Loss on drying

≤0.5%

0.20%

Related substances

Individual impurity: NMT 0.5%

0.05%

Total impurities: NMT 1.0% 0.08%

Sulphated ash

≤0.1%

0.06%

Heavy metals

≤20ppm

Conforms

Assay

98.5%~101.5%

99.3%


Function
Nepafenac is a new type of non-steroidal antipyretic, analgesic and anti-inflammatory drugs (NSAIDs) used for the treatment of ocular pain and inflammation caused by cataract surgery. Compared with traditional NSAIDs, the chemical structure of NSAIDs is beneficial to the rapid penetrating of the cornea and distribution of the drug to its target site. Therefore, it is helpful to reduce the accumulation of drugs on the corneal surface, reduce the occurrence of complications on the surface of the eyeball, and has the advantages of strong penetration, strong targeting effect and small toxic and side effects. On August 19, 2005, the United States Food and Drug Administration (FDA) approved Nepafenamide ophthalmic suspension for the treatment of cataract operation-related pain and inflammation, and it was the first NSAID ophthalmic precursor drug preparation to be approved on the market. Nepafenamide, when administered via ocular Chemicalbook, rapidly passes through the cornea and is converted to aminophenic acid (a NSAID) under the action of eye tissue hydrolase; Aminophenic acid plays an anti-inflammatory and analgesic role by inhibiting prostaglandin H synthase (cyclooxygenase) and blocking the synthesis of prostaglandin. As is well known, prostagranins are one of the mediators of intraocular inflammation, which can lead to the collapse of the blood-aqueous barrier, vasodilation, increased vascular permeability and leukocyte chemotaxis, etc. In addition, prostagranins can also contract the iris sphincter through a non-cholinergic mechanism, causing pupil constriction during and after eye surgery. When administered through the eye, NSAIDs inhibit the synthesis of prostaglandins in the iris, ciliary body, and conjunctiva, thus preventing ocular inflammation and reducing pain associated with it.


Pharmaceutical Grade Nepafenac CAS 78281-72-8
 

 

Medizinische Chemiekalie

LEGALIS.IT, 2023